ADALIMUMAB vs. IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: A REAL-WORLD MULTICENTER STUDY WITH MATCH-ADJUSTED COMPARISONS
Authors
Clinical Medicine and Internal Medicine Residency Program, Department of Clinical and Molecular Sciences, Marche Polytechnic University and Internal Medicine Department, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
Valentino Paci
Clinical Medicine and Internal Medicine Residency Program, Department of Clinical and Molecular Sciences, Marche Polytechnic University and Internal Medicine Department, Azienda Ospedaliero Universitaria delle Marche
Eleonora Celletti
Department of Medicine and Science of Aging, Medical Clinic, SS. Annunziata Hospital of Chieti, "G. D'Annunzio" University of Chieti-Pescara
Alen Zabotti
Rheumatology Institute, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale
Giuseppe Lopalco
Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro"
Raissa Di Zio
Clinical Medicine and Internal Medicine Residency Program, Department of Clinical and Molecular Sciences, Marche Polytechnic University and Internal Medicine Department, Azienda Ospedaliero Universitaria delle Marche
Roberta Foti
Rheumatology Unit, A.O.U. Policlinico S. Marco
Elisa Visalli
Rheumatology Unit, A.O.U. Policlinico S. Marco
Myriam Di Penta
Department of Medicine and Science of Aging, Medical Clinic, SS. Annunziata Hospital of Chieti, "G. D'Annunzio" University of Chieti-Pescara
Alice Agostinelli
Clinical Medicine and Internal Medicine Residency Program, Department of Clinical and Molecular Sciences, Marche Polytechnic University and Internal Medicine Department, Azienda Ospedaliero Universitaria delle Marche
Fabio Massimo Perrotta
Rheumatology and Internal Medicine Department, Molise University
Gianluca Moroncini
Clinical Medicine and Internal Medicine Residency Program, Department of Clinical and Molecular Sciences, Marche Polytechnic University and Internal Medicine Department, Azienda Ospedaliero Universitaria delle Marche
Ennio Lubrano
6Rheumatology and Internal Medicine Department, Molise University
Florenzo Jannone
Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro"
Rosario Foti
Rheumatology Unit, A.O.U. Policlinico S. Marco
Michele Maria Luchetti Gentiloni
Clinical Medicine and Internal Medicine Residency Program, Department of Clinical and Molecular Sciences, Marche Polytechnic University and Internal Medicine Department, Azienda Ospedaliero Universitaria delle Marche
Keywords
Psoriatic Arthritis, Real-World Evidence, Adalimumab, Ixekizumab, Propensity Score Matching, DAPSA Remission
This study compared two biologic drugs, adalimumab and ixekizumab, used to treat psoriatic arthritis in a real-world clinical setting. Both improved joint symptoms, skin involvement, and patient function. After one year, remission rates were similar, but ixekizumab showed greater benefits for skin symptoms and quality of life. This research helps physicians choose the most appropriate treatment based on individual patient characteristics. For patients, it means more personalized, effective care targeted to their main symptoms, improving daily disease management.